ScriptBio AI
Adding Life to Years
Introduction
ScriptBio AI is developing engineered mesenchymal stem cell (MSC) therapies guided by a proprietary AI-Omics engine that identifies disease-driving gene targets from multi-omics data. Our lead indication is knee osteoarthritis. The platform combines causal AI with iPSC-derived cell engineering to deliver targeted tissue repair, addressing root biology, not just symptoms.
Founded by a 16-year stem cell veteran (MIT Sloan MBA '26), with leads in AI/ML (ex-Apple, JPMorgan; NYU Stern) and computational biology (Harvard).
Traction: Company incorporated (Jul 2025) · 20+ customer discovery interviews · AI engine MVP validated (541K-cell atlas, 73% accuracy, top genes match OA literature) · NYU Stern Entrepreneurship Challenge semifinalist · NVIDIA Inception Program partner · MIT Grand Hack — Hack Nation Prize · LabCentral AI BioHub + C10 Labs accepted · YOPE $100K Pitch invited · MIT Sandbox · Academic partnership with Sandra Pinho, PhD (UIC, HSC Aging)
Problem
We are living longer, not healthier. 2.1 billion people will be over 60 by 2050, and over half already live with 2+ chronic diseases. The annual U.S. cost of chronic disease exceeds $4.1 trillion, the majority driven by aging. Yet zero approved therapies target the root biological drivers of age-related disease, every treatment on the market manages symptoms after damage is done.
We start with knee osteoarthritis: 650M+ affected globally, a $119B and rapidly growing market, and no disease-modifying therapy exists. KOA is the ideal beachhead, it has validated clinical endpoints (WOMAC, MRI), a simple outpatient delivery route (single intra-articular injection), and strong payer alignment, where every delayed knee replacement saves $30K–$50K.
Opportunity
ScriptBio AI's AI-Omics engine analyzes molecular differences between young, healthy and aged, diseased tissues to identify the gene factors that restore tissue repair capacity. We engineer iPSC-derived mesenchymal stem cells (MSCs) to express these factors and deliver them locally via knee injection, reducing inflammation, repairing cartilage, and delaying or preventing joint replacement. Our edge: causal multi-omics AI plus iPSC cell engineering, discovery and delivery in one platform. The approach is designed to extend beyond KOA into any age-related tissue degeneration.